Then, DCs migrate to tumor-draining lymph nodes with the help of type I IFNs and cross-activate tumor-specific CD8+ T cells, which induce systemic antitumor immunity to control local and distant tumor growth (Papewalis et al., 2008) (Figure 3). The gene discussed is CD8A; the disease is neoplasm.